AC Immune SA Logo

AC Immune SA

Developing precision medicine to diagnose, treat, and prevent neurodegenerative diseases.

ACIU | NDAQ

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
United States of America
Address:
EPFL INNOVATION PARK, BUILDING B, 0 1015 LAUSANNE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AC Immune SA is a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases. The company focuses on developing innovative ways to diagnose, treat, and prevent conditions such as Alzheimer’s disease, Parkinson’s disease, and other rare neuro-orphan indications. Its broad and diversified pipeline is built on proprietary technology platforms and includes multiple treatment modalities, such as active immunotherapies, monoclonal antibodies, small molecule drugs, and diagnostic agents. These product candidates are designed to target and clear the pathological, misfolded proteins that are central to neurodegeneration. The company's scientific leadership and pipeline are validated through strategic collaborations with global pharmaceutical leaders.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all AC Immune SA filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AC Immune SA

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AC Immune SA via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America ADCT
Addex Therapeutics Ltd. Logo
Developing novel oral allosteric modulators to treat neurological disorders.
United States of America ADXN
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America ACET

Talk to a Data Expert

Have a question? We'll get back to you promptly.